These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27135095)

  • 1. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Feld JJ; Zeuzem S
    N Engl J Med; 2016 Apr; 374(17):1688-9. PubMed ID: 27135095
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Foster GR; Mangia A; Sulkowski M
    N Engl J Med; 2016 Apr; 374(17):1687-8. PubMed ID: 27119242
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Assy N; Barhoum M
    N Engl J Med; 2016 Apr; 374(17):1687. PubMed ID: 27119243
    [No Abstract]   [Full Text] [Related]  

  • 4. Sofosbuvir and Velpatasvir for Patients with HCV Infection.
    Curry MP; Charlton M
    N Engl J Med; 2016 Apr; 374(17):1688. PubMed ID: 27135094
    [No Abstract]   [Full Text] [Related]  

  • 5. Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.
    Ward JW; Mermin JH
    N Engl J Med; 2015 Dec; 373(27):2678-80. PubMed ID: 26575359
    [No Abstract]   [Full Text] [Related]  

  • 6. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
    Ruane P; Strasser SI; Gane EJ; Hyland RH; Shao J; Dvory-Sobol H; Tran T; Stamm LM; Brainard DM; Nyberg L; Shafran S
    J Viral Hepat; 2019 Jun; 26(6):770-773. PubMed ID: 30663168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
    Schreiber J; McNally J; Chodavarapu K; Svarovskaia E; Moreno C
    Hepatology; 2016 Sep; 64(3):983-5. PubMed ID: 27177605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
    Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
    Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.
    Sharara AI; Rustom LBO; Marrache M; Rimmani HH; Bou Daher H; Koussa S; Taher A
    Am J Hematol; 2019 Feb; 94(2):E43-E45. PubMed ID: 30394575
    [No Abstract]   [Full Text] [Related]  

  • 11. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.
    Lee R; Kottilil S; Wilson E
    Hepatol Int; 2017 Mar; 11(2):161-170. PubMed ID: 27928718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
    Weisberg IS; Jacobson IM
    Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
    Douglas MW; Tay ES; Eden JS; George J
    J Infect Dis; 2019 Jul; 220(4):720-722. PubMed ID: 30958539
    [No Abstract]   [Full Text] [Related]  

  • 14. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.
    Jones KM; Shelton ME; Soldano AC; Campbell J
    JAMA Dermatol; 2018 Sep; 154(9):1094-1096. PubMed ID: 30140911
    [No Abstract]   [Full Text] [Related]  

  • 16. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Sucher AJ; Hemstreet BA
    Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
    Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
    van Seyen M; Samson AD; Cullen L; Eastick K; Knol H; Colbers A; Burger DM
    Int J Antimicrob Agents; 2020 Jun; 55(6):105934. PubMed ID: 32156618
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
    Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ
    Clin Infect Dis; 2016 Dec; 63(11):1479-1481. PubMed ID: 27553377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.